SML2259

Lapatinib

≥98% (HPLC)

• Sinónimos: Lapatinib, GD 2016, GSK 572016, GW-572016, GW572016, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine, N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
• Fórmula empírica (notación de Hill): C₂₉H₂₆ClFN₄O₄S
• Número de CAS: 231277-92-2
• Peso molecular: 581.06
• MDL number: MFCD09264194
• UNSPSC Code: 12352200
• NACRES: NA.77

Propiedades

• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O
• InChI: 1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
• InChI key: BCFGMOOMADDAQU-UHFFFAOYSA-N
• Gene Information: human ... EGFR(1956) , ERBB2(2064)

Descripción

Biochem/physiol Actions

Lapatinib acts as a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). It competes for its binding site on the tyrosine kinase domain with adenosine triphosphate (ATP). Lapatinib mediates has been studied in vitro in the inhibition of cell growth as well as and apoptosis induction in several human cancer cells such as breast, lung, vulva, gastric, and head and neck cancer.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H319,H362,H413
• pcodes: P201 - P260 - P263 - P273 - P305 + P351 + P338 - P308 + P313
• Hazard Classifications: Aquatic Chronic 4 - Eye Irrit. 2 - Lact.
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable